摘要
目的:分析依达拉奉右莰醇治疗急性缺血性脑卒中(AIS)疗效的影响因素。方法:选取2021年9月至2022年9月我院收治的AIS住院患者69例,在AIS常规治疗基础上给予依达拉奉右莰醇静脉注射治疗,采用logistic回归分析影响依达拉奉右莰醇疗效的因素。结果:AIS患者以70岁以上、男性居多,依达拉奉右莰醇用药时长大部分集中在5~9 d。年龄、入院时病情、用药时长是依达拉奉右莰醇治疗AIS疗效的影响因素(P<0.05)。结论:依达拉奉右莰醇的用药时长推荐为10~14 d,对于高龄及病情较重的AIS患者,建议尽早采用依达拉奉右莰醇联合其他方法进行治疗。
Objective:To analyze the influencing factors of the therapeutic effect of edaravone and dexborneol on acute ischemic stroke(AIS).Methods:A total of 69 AIS inpatients admitted to our hospital from September 2021 to September 2022 were selected.They were treated by the intravenous injection of edaravone and dexborneol on the basis of routine AIS treatment.Logistic regression analysis was used to analyze the factors affecting the therapeutic effect of edaravone and dexborneol.Results:AIS patients were mostly over 70 years old and male.The majority of duration of medication was concentrated in the 5-9 days.Age,illness severity at admission,and duration of medication were the influencing factors of therapeutic effect of edaravone and dexborneol in the treatment of AIS(P<0.05).Conclusion:The recommended duration of medication for edaravone and dexborneol is 10-14 days.For older and more severe AIS patients,it is suggested that edaravone and dexborneol should be combined with other methods for treatment as as soon as possible.
作者
宋晓玲
罗凝春
任瑶
邱学青
陈甫
郑奇
刘堃
王建兵
奚雪梅
张伟
陈玉红
周志
Song Xiaoling;Luo Ningchun;Ren Yao;Qiu Xueqing;Chen Fu;Zheng Qi;Liu Kun;Wang Jianbing;Xi Xuemei;Zhang Wei;Chen Yuhong;Zhou Zhi(Department of Neurology,Chengfei Hospital,Chengdu,Sichuan 610000,China)
出处
《现代临床医学》
2024年第3期198-200,211,共4页
Journal of Modern Clinical Medicine
关键词
依达拉奉右莰醇
急性缺血性卒中
疗效
影响因素
edaravone and dexborneol
acute ischemic stroke
therapeutic effect
influencing factors
